Europe Anti-Viral Therapies Market to Grow at a CAGR of 8.1% to reach US$ 21,122.66 Million from 2020 to 2027

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. Europe Anti-Viral Therapies Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. Europe Anti-Viral Therapies Market – Key Market Dynamics

5.1 Growth Drivers

5.2 Market Opportunities

5.3 Future Trends

5.4 Impact of Drivers and Restraints

6. Europe Anti-Viral Therapies Market Regional Analysis

6.1 Europe Anti-Viral Therapies Market Overview

6.2 Europe Anti-Viral Therapies Market Revenue 2017-2027 (US$ Million)

6.3 Europe Anti-Viral Therapies Market Forecast Analysis

7. Europe Anti-Viral Therapies Market Analysis – by Type

7.1 Generic Drugs

7.1.1 Overview
7.1.2 Generic Drugs: Europe Anti-Viral Therapies Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Branded Drugs

7.2.1 Overview
7.2.2 Branded Drugs: Europe Anti-Viral Therapies Market – Revenue and Forecast to 2031 (US$ Million)

8. Europe Anti-Viral Therapies Market Analysis – by Mechanism of Action

8.1 Nucleotide Polymerase Inhibitors

8.1.1 Overview
8.1.2 Nucleotide Polymerase Inhibitors: Europe Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)

8.2 Reverse Transcriptase Inhibitors

8.2.1 Overview
8.2.2 Reverse Transcriptase Inhibitors: Europe Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)

8.3 Protease Inhibitors

8.3.1 Overview
8.3.2 Protease Inhibitors: Europe Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)

9. Europe Anti-Viral Therapies Market Analysis – by Application

9.1 HIV

9.1.1 Overview
9.1.2 Protease Inhibitors: Europe Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)

9.2 Hepatitis

9.2.1 Overview
9.2.2 Protease Inhibitors: Europe Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)

9.3 Virus Influenza

9.3.1 Overview
9.3.2 Protease Inhibitors: Europe Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)

9.4 Herpes

9.4.1 Overview
9.4.2 Protease Inhibitors: Europe Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)

9.5 Other Applications

9.5.1 Overview
9.5.2 Protease Inhibitors: Europe Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)

10. Europe Anti-Viral Therapies Market – Europe Analysis

10.1 Europe

10.1.1 Europe Anti-Viral Therapies Market Breakdown, by Key Country, 2020 and 2027 (%)
10.1.1.1 Europe Anti-Viral Therapies Market – Revenue and Forecast Analysis – by Country
10.1.1.1 UK: Europe Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.1.1 UK: Europe Anti-Viral Therapies Market Breakdown, by Type
10.1.1.1.2 UK: Europe Anti-Viral Therapies Market Breakdown, by Mechanism of Action
10.1.1.1.3 UK: Europe Anti-Viral Therapies Market Breakdown, by Application

10.1.1.2 Germany: Europe Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.2.1 Germany: Europe Anti-Viral Therapies Market Breakdown, by Type
10.1.1.2.2 Germany: Europe Anti-Viral Therapies Market Breakdown, by Mechanism of Action
10.1.1.2.3 Germany: Europe Anti-Viral Therapies Market Breakdown, by Application

10.1.1.3 France: Europe Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.3.1 France: Europe Anti-Viral Therapies Market Breakdown, by Type
10.1.1.3.2 France: Europe Anti-Viral Therapies Market Breakdown, by Mechanism of Action
10.1.1.3.3 France: Europe Anti-Viral Therapies Market Breakdown, by Application

10.1.1.4 Russia: Europe Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.4.1 Russia: Europe Anti-Viral Therapies Market Breakdown, by Type
10.1.1.4.2 Russia: Europe Anti-Viral Therapies Market Breakdown, by Mechanism of Action
10.1.1.4.3 Russia: Europe Anti-Viral Therapies Market Breakdown, by Application

10.1.1.5 Italy: Europe Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.5.1 Italy: Europe Anti-Viral Therapies Market Breakdown, by Type
10.1.1.5.2 Italy: Europe Anti-Viral Therapies Market Breakdown, by Mechanism of Action
10.1.1.5.3 Italy: Europe Anti-Viral Therapies Market Breakdown, by Application

10.1.1.6 Rest of Europe: Europe Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.6.1 Rest of Europe: Europe Anti-Viral Therapies Market Breakdown, by Type
10.1.1.6.2 Rest of Europe: Europe Anti-Viral Therapies Market Breakdown, by Mechanism of Action
10.1.1.6.3 Rest of Europe: Europe Anti-Viral Therapies Market Breakdown, by Application

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Europe Anti-Viral Therapies Market Industry Landscape

12.1 Overview

12.2 Mergers and Acquisitions

12.3 Agreements, Collaborations, and Joint Ventures

12.4 New Product Launches

12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 AbbVie Inc.

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 GlaxoSmithKline plc

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 AstraZeneca

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 F. HOFFMANN-LA ROCHE LTD

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Johnson and Johnson Services, Inc.

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - E Market

The List of Companies - Europe Anti-Viral Therapies Market

AbbVie Inc.
GlaxoSmithKline plc
AstraZeneca
F. HOFFMANN-LA ROCHE LTD
Johnson and Johnson Services, Inc.